23 May, 2017
JPMorgan Chase & Co. reaffirmed a "neutral" rating on shares of GlaxoSmithKline plc in a research note on Tuesday, February 7th. The Orleans Capital Management Corp holds 14,394 shares with $554,000 value, down from 32,507 last quarter. Tower Bridge Advisors' holdings in GlaxoSmithKline plc were worth $933,000 at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. M&R Capital Management Inc. increased its stake in GlaxoSmithKline plc by 22.5% in the fourth quarter. The institutional investor owned 29,567 shares of the pharmaceutical company's stock at the end of the first quarter. GW Henssler & Associates Ltd. boosted its position in shares of GlaxoSmithKline plc by 2.7% in the third quarter. Raymond James Trust sold 9,424 shares as Glaxo Smithkline Sponsored Plc (GSK)'s stock rose 5.47%. Finally, Norway Savings Bank bought a new stake in GlaxoSmithKline plc during the fourth quarter worth about $139,000. Park National Corp OH now owns 6,314 shares of the pharmaceutical company's stock worth $266,000 after buying an additional 118 shares in the last quarter.
WARNING: "GlaxoSmithKline plc (GSK) Position Held by FCM Investments TX" was published by Chaffey Breeze and is the property of of Chaffey Breeze. The company's stock had a trading volume of 7,047,699 shares. GlaxoSmithKline plc has a 52 week low of $37.20 and a 52 week high of $45.58. Oak Associates Ltd who had been investing in Glaxo Smithkline Ads for a number of months, seems to be bullish on the $104.95 billion market cap company. The company's 50 day moving average is $41.86 and its 200-day moving average is $40.27. GlaxoSmithKline plc (ADR) (NYSE:GSK) has risen 4.26% since May 23, 2016 and is uptrending. The pharmaceutical company reported $0.62 EPS for the quarter, hitting analysts' consensus estimates of $0.62. The business had revenue of $9.23 billion during the quarter, compared to analyst estimates of $9.09 billion. GlaxoSmithKline plc had a net margin of 3.11% and a return on equity of 100.68%. Analysts expect that GlaxoSmithKline plc will post $2.82 earnings per share for the current year. The company was maintained on Friday, August 12 by Argus Research. This represents a $1.93 annualized dividend and a yield of 4.46%. The ex-dividend date of this dividend is Thursday, May 11th. This is an increase from GlaxoSmithKline plc's previous quarterly dividend of $0.46. The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) has "Underperform" rating given on Wednesday, September 14 by BNP Paribas. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of United States & worldwide copyright and trademark law. The legal version of this story can be viewed at https://sportsperspectives.com/2017/05/22/glaxosmithkline-plcs-gsk-buy-rating-reiterated-at-hsbc-holdings-plc-updated-updated.html.
GSK has been the subject of several research analyst reports. JPMorgan Chase & Co. reissued a neutral rating on shares of GlaxoSmithKline plc in a research note on Monday, January 30th. Also, insider Vivienne Cox acquired 335 shares of GlaxoSmithKline plc stock in a transaction that occurred on Wednesday, April 26th. JPMorgan Chase & Co. reiterated a "neutral" rating on shares of GlaxoSmithKline plc in a research report on Tuesday, February 7th. The stock presently has a consensus rating of Hold and an average price target of GBX 1,743.36 ($22.68). They issued a "reduce" rating on the stock. Three research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and eight have issued a buy rating to the stock.
The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) has "Overweight" rating given on Friday, September 23 by Piperjaffray.
